May 2, 2023 11:31 AM EDTUpdated 01:12 PM
People

Ex­elix­is gives more de­tails be­hind Far­al­lon proxy fight

Paul Schloesser

Associate Editor

On­col­o­gy biotech Ex­elix­is is de­fend­ing its busi­ness amid a proxy fight with a hedge fund that has crit­i­cized the com­pa­ny’s R&D strat­e­gy and spend­ing. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times